Ananda Gets FDA Approval to Study CBD as Adjunctive Treatment for OUD
Ananda Scientific announced recently that it has received approval by the Food and Drug Administration (FDA) for its investigational new drug application for a clinical trial of its Nantheia ATL5, an investigational drug that uses CBD as an adjunctive treatment for opioid use disorder.
Backed by scientists in the United States and Israel, Ananda Scientific is a biotech firm that is developing cannabinoids in collaboration with Hebrew University and Jersusalem and Ben Gurion University. Per its website, the company’s focus is on delivery technologies that make botanical compounds “bioavailable, water soluble, and shelf-life stable through nano-sized, self-assembling liquid structures.”
The study of Nantheia ATL5 will be conducted at UCLA, and it will be led by principal investigators Edythe London, PhD, distinguished professor of psychiatry and biobehavioral sciences and molecular and medicinal pharmacology at UCLA’s Semel Institute at the Geffen School of Medicine, and Richard De La Garza II, PhD, professor of psychiatry and biobehavioral sciences at the institute. The trial is being funded by the National Institute on Drug Abuse (NIDA).
“This is the fourth IND approval for our investigational drug Nantheia product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications,” Ananda CEO Sohail R. Zaidi said in a news release. “This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need.”
Reference
